Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 10/20 | 0.68 |
| ▸ | MEN1 | O00255 | 8/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | MGAM | O43451 | 8/20 | 0.66 |
| ▸ | SI | P14410 | 8/20 | 0.66 |
| ▸ | MGAM2 | Q2M2H8 | 8/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17264096 | 0.81 | GAA (0.67) | GAAMEN1KMT2AMAPTLMNA | |
| SCHEMBL7930002 | 0.75 | GAA (0.60) | GAAMEN1KMT2AMAPTLMNA | |
| SCHEMBL4408570 | 0.74 | GAA (0.61) | GAAMEN1KMT2AMAPTLMNA | |
| SCHEMBL4487938 | 0.74 | GAA (0.61) | GAAMEN1KMT2AMAPTLMNA | |
| SCHEMBL10288995 | 0.74 | TDP1 (0.67) | GAAMEN1KMT2AMAPTLMNA | |
| SCHEMBL3174768 | 0.73 | MAPT (0.62) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL3253804 | 0.73 | ROCK1 (0.68) | GAAMEN1KMT2AMAPTLMNA | |
| SCHEMBL2452315 | 0.73 | ELOVL1 (0.72) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL15630753 | 0.73 | KMT2A (0.63) | GAAMEN1KMT2AMAPTLMNA | |
| SCHEMBL6157729 | 0.72 | SCD (0.74) | MEN1KMT2AMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | GAA 148/4885MEN1 3957/4885KMT2A 3813/4885 |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | CFTR, ABCC5, QPCT | GAA 349/4885MEN1 4634/4885KMT2A 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.